FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892590228> ?p ?o ?g. }

• W2892590228 abstract "Abstract Background Recurrent, platin-resistant ovarian cancer (rPROC) has a poor survival. Even with the AURELIA trial, which is the best available treatment today, progression-free survival (PFS) is still only 6.7 months from the start of the second-line chemotherapy. Innovative, effective therapies are urgently needed. Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) is a novel drug delivery system for administering drugs into the abdomen. PIPAC with cisplatin and doxorubicin (PIPAC C/D) may be safely used at an intraperitoneal dose of 10.5 mg/m 2 and 2.1 mg/m 2 , respectively. Systemic toxicity of this therapy is low. In a phase II trial with 53 women, 62 % patients had an objective tumor response. Tumor regression on histology was observed in 76 % patients who underwent all three PIPACs. Randomized phase III studies are now required to evaluate the effect of PIPAC C/D compared to other standard treatments (sequential or simultaneous applications with systemic chemotherapy). Methods The present phase III study is a prospective, open, randomized, multicentric pivotal trial. A total of 244 patients will be randomly assigned (1:1) to the control (A) or to the experimental (B) group. Group A: Systemic palliative chemotherapy, physician’s best choice (monotherapy consisting of pegylated liposomal doxorubicin or topotecan or gemcitabine or paclitaxel weekly. Bevacizumab can be used in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin). Group B: Intraperitoneal chemotherapy, 3×PIPAC C/D, performed every 6 weeks. Combination with systemic therapy is not allowed. Treatment is continued until disease progression, death, or patient refusal. In case of progression, no recommendation for further therapy is given by protocol. Patients are allowed to receive PIPAC C/D or systemic chemotherapy after study termination. The primary endpoint is PFS (according to RECIST v1.1) or death from any cause. The co-primary endpoint is the health-related quality of life (HRQoL) measured as the global health status (GHS, QLQ-30 of EORTC). Secondary outcomes comprise overall survival, safety (CTCAE 5.0), and tumor response according to peritoneal regression grading score (PRGS). Discussion We expect PIPAC C/D to control peritoneal disease and preserve the QoL on this subset of patients. Trial registration The EudraCT number 2018-003664-31" @default.
• W2892590228 created "2018-10-05" @default.
• W2892590228 creator A5002753743 @default.
• W2892590228 creator A5010130023 @default.
• W2892590228 creator A5013148496 @default.
• W2892590228 creator A5026048739 @default.
• W2892590228 creator A5041520697 @default.
• W2892590228 creator A5064757063 @default.
• W2892590228 creator A5088879599 @default.
• W2892590228 date "2018-09-25" @default.
• W2892590228 modified "2023-09-30" @default.
• W2892590228 title "PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer" @default.
• W2892590228 cites W171868192 @default.
• W2892590228 cites W1964023152 @default.
• W2892590228 cites W1967820079 @default.
• W2892590228 cites W1994741325 @default.
• W2892590228 cites W2041178952 @default.
• W2892590228 cites W2060590865 @default.
• W2892590228 cites W2113466571 @default.
• W2892590228 cites W2156804105 @default.
• W2892590228 cites W2170928115 @default.
• W2892590228 cites W2528228811 @default.
• W2892590228 cites W2737389832 @default.
• W2892590228 cites W2799675510 @default.
• W2892590228 doi "https://doi.org/10.1515/pp-2018-0114" @default.
• W2892590228 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6405004" @default.
• W2892590228 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30911662" @default.
• W2892590228 hasPublicationYear "2018" @default.
• W2892590228 type Work @default.
• W2892590228 sameAs 2892590228 @default.
• W2892590228 citedByCount "26" @default.
• W2892590228 countsByYear W28925902282019 @default.
• W2892590228 countsByYear W28925902282020 @default.
• W2892590228 countsByYear W28925902282021 @default.
• W2892590228 countsByYear W28925902282022 @default.
• W2892590228 countsByYear W28925902282023 @default.
• W2892590228 crossrefType "journal-article" @default.
• W2892590228 hasAuthorship W2892590228A5002753743 @default.
• W2892590228 hasAuthorship W2892590228A5010130023 @default.
• W2892590228 hasAuthorship W2892590228A5013148496 @default.
• W2892590228 hasAuthorship W2892590228A5026048739 @default.
• W2892590228 hasAuthorship W2892590228A5041520697 @default.
• W2892590228 hasAuthorship W2892590228A5064757063 @default.
• W2892590228 hasAuthorship W2892590228A5088879599 @default.
• W2892590228 hasBestOaLocation W28925902281 @default.
• W2892590228 hasConcept C126322002 @default.
• W2892590228 hasConcept C141071460 @default.
• W2892590228 hasConcept C143998085 @default.
• W2892590228 hasConcept C168563851 @default.
• W2892590228 hasConcept C2776694085 @default.
• W2892590228 hasConcept C2777292972 @default.
• W2892590228 hasConcept C2778239845 @default.
• W2892590228 hasConcept C2780258809 @default.
• W2892590228 hasConcept C2781209748 @default.
• W2892590228 hasConcept C2781303535 @default.
• W2892590228 hasConcept C71924100 @default.
• W2892590228 hasConcept C90924648 @default.
• W2892590228 hasConceptScore W2892590228C126322002 @default.
• W2892590228 hasConceptScore W2892590228C141071460 @default.
• W2892590228 hasConceptScore W2892590228C143998085 @default.
• W2892590228 hasConceptScore W2892590228C168563851 @default.
• W2892590228 hasConceptScore W2892590228C2776694085 @default.
• W2892590228 hasConceptScore W2892590228C2777292972 @default.
• W2892590228 hasConceptScore W2892590228C2778239845 @default.
• W2892590228 hasConceptScore W2892590228C2780258809 @default.
• W2892590228 hasConceptScore W2892590228C2781209748 @default.
• W2892590228 hasConceptScore W2892590228C2781303535 @default.
• W2892590228 hasConceptScore W2892590228C71924100 @default.
• W2892590228 hasConceptScore W2892590228C90924648 @default.
• W2892590228 hasIssue "3" @default.
• W2892590228 hasLocation W28925902281 @default.
• W2892590228 hasLocation W28925902282 @default.
• W2892590228 hasLocation W28925902283 @default.
• W2892590228 hasLocation W28925902284 @default.
• W2892590228 hasOpenAccess W2892590228 @default.
• W2892590228 hasPrimaryLocation W28925902281 @default.
• W2892590228 hasRelatedWork W1970921743 @default.
• W2892590228 hasRelatedWork W1980023082 @default.
• W2892590228 hasRelatedWork W2028929367 @default.
• W2892590228 hasRelatedWork W2085978374 @default.
• W2892590228 hasRelatedWork W2100029565 @default.
• W2892590228 hasRelatedWork W2138943929 @default.
• W2892590228 hasRelatedWork W2187491254 @default.
• W2892590228 hasRelatedWork W2390863976 @default.
• W2892590228 hasRelatedWork W2941436122 @default.
• W2892590228 hasRelatedWork W3152350340 @default.
• W2892590228 hasVolume "3" @default.
• W2892590228 isParatext "false" @default.
• W2892590228 isRetracted "false" @default.
• W2892590228 magId "2892590228" @default.
• W2892590228 workType "article" @default.